HTA25 Diverging Relative Clinical Benefit Assessment Across HAS and G-BA: A Forecast for EU HTA in Oncology Drugs
Abstract
Authors
F Tolkmitt D Chavez AH Alani M Bergsteedt M Mills P Kanavos
F Tolkmitt D Chavez AH Alani M Bergsteedt M Mills P Kanavos
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now